Interesting #EndoPath data? Send us your article! Fast turn around & expert reviewers! Make our journal your voice! link.springer.com/journal/12…

🚨 c-MYC may help distinguish neuroendocrine carcinomas (NEC) from tumors (NET). In 1,380 neuroendocrine neoplasms, c-MYC was expressed in 43% of NEC vs 2% of NET/carcinoids. Strong positivity may support NEC classification in borderline cases! link.springer.com/article/10…

🔬 Ampullary somatostatin-producing (D-cell) neuroendocrine tumors are rare and poorly characterized. A multicenter study reveals distinctive diagnostic features and potentially actionable kinase-related alterations in 64% of tumors! link.springer.com/article/10…

ECP2026 in Stockholm with endocrine pathologists Christofer Juhlin, Sylvia Asa and Ozgur Mete 🇸🇪🔬

Endocrine pathology came out in full force at ECP2026 in Stockholm, Sweden! Depicted here are three leaders in the field who need no formal introduction: Silvia Uccella, Ozgur Mete and Sylvia Asa!

🇸🇪 Endocrine Pathology at #ECP2026 in Stockholm! Monday highlights: 🧩 The Endocrine Challenge, 🏆 Best Poster Session & 🧬 Adrenal and paraganglia: are there new kids on the blocks? From morphology to molecular diagnostics - lots to discuss! espcongress.org/

Can we better predict recurrence in non-functioning pancreatic NET? 🧬 No recurrences occurred in tumors with isolated Menin loss, vs 48% with ATRX/DAXX loss - highlighting the potential of molecular risk stratification to guide follow-up. Read it here: link.springer.com/article/10…

Rare. Aggressive. Biologically complex. 🧬 Bladder neuroendocrine neoplasms challenge current classifications. This review uncovers their molecular heterogeneity and proposes a bladder-specific framework to sharpen diagnosis and personalized medicine. link.springer.com/article/10…

🧬 New PPGL genetics research: Germline testing found pathogenic variants in nearly one-third of 110 pheo/paraganglioma patients, highlighting the value of tiered testing and equitable variant interpretation across diverse populations. link.springer.com/article/10…

🔬 New in Endocrine Pathology: Necrosis in paragangliomas (only 3.9% of cases) is linked to 75% metastasis rate (vs 10%), larger tumors & cardiovascular complications. Cystic changes don't affect outcomes. Pathology matters for risk stratification! link.springer.com/article/10…

💡 A new genetic cause of hereditary hyperparathyroidism? New findings implicate fumarate hydratase (FH) deficiency in a subset of parathyroid adenomas - expanding the phenotypic spectrum of FH tumor predisposition syndromes! link.springer.com/article/10…

🩸 Could ctDNA improve monitoring of adrenocortical carcinoma? In 87 tests from 20 patients, ctDNA showed 88% sensitivity, 91.7% specificity - and strongly correlated with tumor burden (R=0.844). Promising evidence for personalized ACC surveillance! link.springer.com/article/10…

Where do rare renal neuroendocrine tumors come from? 🕵🏼‍♀️ Genomic & transcriptomic profiling of RenNETs reveals neuroendocrine programs, universal SSTR2A expression and genetic evidence that GI-type epithelium may be a precursor in some cases. link.springer.com/article/10…

🦋 Multifocal fibrosing thyroiditis: rarer - or simply underrecognized? Found in 1.56% of 1,736 thyroid resections, MFT can mimic papillary thyroid carcinoma and frequently coexists with other thyroid lesions. A closer look at this enigmatic entity 👇 link.springer.com/article/10…

🧬 Could RNA splicing help explain PanNET heterogeneity? Analysis of 174 tumors reveals 3 distinct “spliceosomic” groups with unique clinical, molecular & splicing profiles - opening new avenues for biomarkers and personalized therapy. link.springer.com/article/10…

🧬 Are all ALK rearrangements in oncocytic thyroid tumors equal? Not necessarily. New research shows STRN::ALK transcript heterogeneity, only canonical in-frame fusions showed ALK protein expression. Resd why FISH-positive ≠ ALK-driven 👇 link.springer.com/article/10…

Are gallbladder neuroendocrine tumors really aggressive? A new study in Endocrine Pathology suggests most GB-NETs are small, low-grade, and indolent, with tumor size and grade emerging as key predictors of metastatic risk. link.springer.com/article/10…

How does adrenocortical carcinoma become metastatic? New research suggests that widespread chromosomal alterations occur early and are retained throughout tumor evolution, identifying chromosomal instability as a key driver! Read more: link.springer.com/article/10…

Is it time to move beyond the typical/atypical carcinoid classification? Using data from >700 pulmonary NETs, researchers developed a reproducible grading system (Ki-67 and mitotic count) that outperformed traditional histology in predicting outcome. link.springer.com/article/10…